Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition

Affiliations

¹ Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA ;
² Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA;
³ Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Editorial

Moshe C Ornstein et al. Transl Androl Urol. 2016 Aug.

. 2016 Aug;5(4):616-9.

doi: 10.21037/tau.2016.05.13.

¹ Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA ;
² Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA;
³ Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.
Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON. Faltermeier CM, et al. Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112. Epub 2015 Nov 30. Proc Natl Acad Sci U S A. 2016. PMID: 26621741 Free PMC article.

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42. 10.1056/NEJM200104053441402 - DOI - PubMed
1. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-42. 10.1016/0092-8674(84)90438-0 - DOI - PubMed
1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. 10.1056/NEJMoa050753 - DOI - PubMed
1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16. 10.1056/NEJMoa1103782 - DOI - PMC - PubMed
1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015;373:2425-37. 10.1056/NEJMoa1509388 - DOI - PMC - PubMed